Literature DB >> 20506305

Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells.

Sheela Shrestha1, Barry Wershil, John F Sarwark, Timothy B Niewold, Teresa Philipp, Lauren M Pachman.   

Abstract

OBJECTIVE: To investigate the distribution of mast cells and dendritic cell (DC) subsets in paired muscle and skin (lesional/nonlesional) from untreated children with juvenile dermatomyositis (DM).
METHODS: Muscle and skin biopsy samples (4 skin biopsy samples with active rash) from 7 patients with probable/definite juvenile DM were compared with muscle and skin samples from 10 healthy pediatric controls. Mast cell distribution and number were assessed by toluidine blue staining and analyzed by Student's t-test. Immunohistochemical analysis was performed to identify mature DCs, myeloid DCs (MDCs), and plasmacytoid DCs (PDCs) by using antibodies against DC-LAMP, blood dendritic cell antigen 1 (BDCA-1), and BDCA-2, respectively. Myxovirus resistance protein A (MxA) staining indicated active type I interferon (IFN) signaling; positive staining was scored semiquantitatively and analyzed using the Mann-Whitney U test.
RESULTS: Both inflamed and nonlesional skin from patients with juvenile DM contained more mast cells than did skin from pediatric controls (P = 0.029), and comparable numbers of mast cells were present in lesional and nonlesional skin. Interestingly, mast cell numbers were greater in skin than in paired muscle tissue from patients with juvenile DM (P = 0.014) and were not increased in muscle from patients with juvenile DM compared with control muscle. Both muscle and skin from patients with juvenile DM showed more mature PDCs and MxA staining than did their corresponding control tissues (P < 0.05). In both muscle and skin from patients with juvenile DM and in pediatric control muscle, there were fewer MDCs than PDCs, and the distributions of MDCs and PDCs were similar in pediatric control skin samples.
CONCLUSION: The identification of mast cells in skin (irrespective of rash) from patients with juvenile DM, but not in paired muscle tissue, suggests that they have a specific role in juvenile DM skin pathophysiology. In skin from patients with juvenile DM, increased numbers of PDCs and increased expression of type I IFN-induced protein suggest a selective influence on T cell differentiation and subsequent effector function.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20506305      PMCID: PMC3312790          DOI: 10.1002/art.27529

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  47 in total

1.  Dendritic cell modulation by mast cells controls the Th1/Th2 balance in responding T cells.

Authors:  Alessandra Mazzoni; Reuben P Siraganian; Cynthia A Leifer; David M Segal
Journal:  J Immunol       Date:  2006-09-15       Impact factor: 5.422

2.  Myeloid dendritic cells in inclusion-body myositis and polymyositis.

Authors:  Steven A Greenberg; Geraldine S Pinkus; Anthony A Amato; Jack L Pinkus
Journal:  Muscle Nerve       Date:  2007-01       Impact factor: 3.217

3.  Cromolyn administration (to block mast cell degranulation) reduces necrosis of dystrophic muscle in mdx mice.

Authors:  Hannah G Radley; Miranda D Grounds
Journal:  Neurobiol Dis       Date:  2006-06-23       Impact factor: 5.996

4.  MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement.

Authors:  Kevin A O'Connor; Kathy A Abbott; Brad Sabin; Maxine Kuroda; Lauren M Pachman
Journal:  Clin Immunol       Date:  2006-07-21       Impact factor: 3.969

5.  Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus.

Authors:  Joerg Wenzel; Eva Wörenkämper; Silke Freutel; Stefanie Henze; Otto Haller; Thomas Bieber; Thomas Tüting
Journal:  J Pathol       Date:  2005-03       Impact factor: 7.996

6.  Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis.

Authors:  A Reiff; D J Rawlings; B Shaham; E Franke; L Richardson; I S Szer; B H Bernstein
Journal:  J Rheumatol       Date:  1997-12       Impact factor: 4.666

7.  Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians.

Authors:  Gulnara Mamyrova; Terrance P O'Hanlon; Jason B Monroe; Danielle Mercatante Carrick; James D Malley; Sharon Adams; Ann M Reed; Ejaz A Shamim; Laura James-Newton; Frederick W Miller; Lisa G Rider
Journal:  Arthritis Rheum       Date:  2006-12

8.  Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis.

Authors:  J Wenzel; R Schmidt; J Proelss; S Zahn; T Bieber; T Tüting
Journal:  Clin Exp Dermatol       Date:  2006-07       Impact factor: 3.470

9.  Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis.

Authors:  Steven A Greenberg; Jack L Pinkus; Geraldine S Pinkus; Travis Burleson; Despina Sanoudou; Rabi Tawil; Richard J Barohn; David S Saperstein; Hannah R Briemberg; Maria Ericsson; Peter Park; Anthony A Amato
Journal:  Ann Neurol       Date:  2005-05       Impact factor: 10.422

10.  Ultraviolet B irradiation selectively increases the production of interleukin-8 in human cord blood-derived mast cells.

Authors:  I Endoh; N Di Girolamo; T Hampartzoumian; B Cameron; C L Geczy; N Tedla
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

View more
  34 in total

1.  Mast cells and type I interferon responses in the skin of patients with juvenile dermatomyositis: are current therapies just scratching the surface?

Authors:  Lisa G Rider; Frederick W Miller
Journal:  Arthritis Rheum       Date:  2010-09

Review 2.  Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1.

Authors:  R Goldbach-Mansky
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

Review 3.  Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies.

Authors:  Lisa G Rider; James D Katz; Olcay Y Jones
Journal:  Rheum Dis Clin North Am       Date:  2013-09-19       Impact factor: 2.670

Review 4.  Update on outcome assessment in myositis.

Authors:  Lisa G Rider; Rohit Aggarwal; Pedro M Machado; Jean-Yves Hogrel; Ann M Reed; Lisa Christopher-Stine; Nicolino Ruperto
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

5.  Juvenile dermatomyositis: new insights and new treatment strategies.

Authors:  Neil Martin; Charles K Li; Lucy R Wedderburn
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-02       Impact factor: 5.346

Review 6.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.

Authors:  Angela B Robinson; Ann M Reed
Journal:  Nat Rev Rheumatol       Date:  2011-09-27       Impact factor: 20.543

Review 7.  Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity.

Authors:  Lauren M Pachman; Amer M Khojah
Journal:  J Pediatr       Date:  2018-04       Impact factor: 4.406

Review 8.  Type I interferon in rheumatic diseases.

Authors:  Theresa L Wampler Muskardin; Timothy B Niewold
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

Review 9.  Fueling autoimmunity: type I interferon in autoimmune diseases.

Authors:  Jeremy Di Domizio; Wei Cao
Journal:  Expert Rev Clin Immunol       Date:  2013-03       Impact factor: 4.473

Review 10.  Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications.

Authors:  E M Moran; F L Mastaglia
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.